U.S. Secondary Hyperparathyroidism Treatment (SHPT) Market to Reach USD 7.06 Billion by 2026; Increasing Renal Diseases Will Support Growth

The U.S. secondary hyperparathyroidism treatment (SHPT) market size is predicted to reach USD 7.06 Billion by 2026. Increasing patient pool for dialysis is a key factor driving the SHPT market, says Fortune Business insights in a report, titled “Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share & Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital & Retail Pharmacies, Online Channels, and Others), and Region Forecast 2019-2026.” The secondary hyperparathyroidism treatment market was valued at 4.34 Billion in 2018 and is expected to exhibit a CAGR of 9.0% between 2019-2026.

The secondary hyperparathyroidism treatment (SHPT) market can be segmented into hospital & retail pharmacies, online channels, and others on the basis of distribution channel. The hospital & retail pharmacies segment holds maximum share in the secondary hyperparathyroidism treatment (SHPT) market. Hospital & retail pharmacies are estimated to emerge as the leading distribution channel for secondary hyperparathyroidism therapeutics in the U.S. owing to the increasing number of dialysis facilities in the country and availability of SHPT therapeutics with significant discounts in hospital pharmacies. For instance, there were over 152 dialysis facilities per 1,000 patients in Midwest region of the U.S., and around 14.3 facilities per 1,000 patients in North Dakota State of the Midwest region, in 2016.

Rising Patient Pool for Dialysis Will Enable Growth

The surge in renal complications and disease among the U.S population is one of the key SHPT market trends that will contribute to its growth.  The rising prevalence of chronic kidney disease and (CKD) and End-stage Renal Disease (ESRD) will have a positive impact on the secondary hyperparathyroidism treatment market medication during the forecast period. The rising cases of diabetes among general populous is predicted to boost the secondary hyperparathyroidism treatment (SHPT) market growth.

For Instance, 9.4% of the population in the U.S. is diabetic and as a fact 40% of the patients with diabetes develop nephropathy diabetes, patients in the U.S. constitute around 12 million patients of CKD. Furthermore, the approval from the U.S. health regulatory body for the generic Cinacalcet tablets will stimulate the secondary hyperparathyroidism treatment market guidelines. For instance, LUPIN received approval from the US health regulatory body for the generic Cinacalcet tablets used in treatment of excess parathyroid hormone.

Vitamin D Segment Analogues To Account For Highest Share

On the basis of drug class, the secondary hyperparathyroidism treatment market is segmented into calcimimetics, Vitamin D analogues, and phosphate binders.

The Vitamin D analogues segment dominated the U.S. market in 2018 with a  share of 48.9%. The segment is expected to remain dominant through the forecast period, owing to the improved diagnosis of vitamin D insufficiency with the help of advanced vitamin D testing tools in the country. According to OPKO Health, Inc., one of the leading manufacturers of vitamin D analogue Rayaldee for SHPT, the test volume of vitamin D in the U.S. was 70 million in 2016. Furthermore, Calcimimetics accounted for the second-largest share in terms of revenue in 2018 and is expected to expand with a relatively significant CAGR during 2019-2026. 

Rising Geriatric Population Will Enable Growth

As per the report, the SHPT market on the basis of geography is segmented as West, Midwest, South, and Northeast regions. South region generated a revenue of USD 1.93 Billion in 2018 and is expected to emerge dominant in the U.S. market during the forecast period owing to the availability of a significant number of dialysis facilities with strategic presence of leading dialysis clinic networks such as Fresenius Care, DaVita, etc. in the region. In addition, the rising prevalence of secondary hyperparathyroidism in the southern region owing to the presence of the geriatric population with kidney disease will further boost growth in the South region.

Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

The U.S. Secondary Hyperparathyroidism Treatment (SHPT) Market Is Segmented ssinto: